We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
PerkinElmer’s New LANCE® Ultra cAMP Detection Kit Facilitates Screening of Complex GPCRs
Product News

PerkinElmer’s New LANCE® Ultra cAMP Detection Kit Facilitates Screening of Complex GPCRs

PerkinElmer’s New LANCE® Ultra cAMP Detection Kit Facilitates Screening of Complex GPCRs
Product News

PerkinElmer’s New LANCE® Ultra cAMP Detection Kit Facilitates Screening of Complex GPCRs


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "PerkinElmer’s New LANCE® Ultra cAMP Detection Kit Facilitates Screening of Complex GPCRs"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

PerkinElmer, Inc., has announced the launch of its new LANCE® Ultra cAMP Detection Kit. Designed for screening and profiling of G-protein coupled receptors (GPCRs) as tools in the search for potential therapeutics, the LANCE® Ultra kit offers three times the sensitivity using at least 80 percent fewer cells than other kits currently on the market, the company claims.

The new LANCE offering enhances PerkinElmer’s position as the industry leader in providing quality assays for high throughput screening and profiling of GPCRs. This new kit facilitates pharmacological studies of challenging receptors involved in several diseases, including cancer and inflammatory, metabolic and neurodegenerative disorders.

“As the drug discovery processes continue to evolve, there is an increased demand for more robust and highly sensitive methods of measuring responses to GPCRs, which currently form over 40 percent of all drug targets. We’ve addressed this need with the new LANCE Ultra cAMP detection kit. Researchers can now take advantage of a wider assay window and dynamic range that provides for more accurate results, even when miniaturizing protocols for the most ‘difficult to screen’ targets, including Gi-coupled GPCR antagonist assays,” said Martina Bielefeld-Sévigny, PhD, vice president and general manager, Drug Discovery and Research Reagent Solutions, Bio-discovery, PerkinElmer.

The increased sensitivity of the LANCE Ultra cAMP Detection Kit enables scientists to detect low levels of cAMP without the need to re-engineer cell lines. This assay uses a simple TR-FRET protocol for easy adoption in a range of HTS applications, including 1,536-well formats. Furthermore, as many high throughput assays fail to generate reproducible data when cAMP levels are very low, the new kit maximizes signal stability and provides new insights into GPCRs.

LANCE Ultra utilizes PerkinElmer’s proprietary ULight™ emission dye, for high efficiency signal-to-noise ratios. LANCE Ultra is optimized for use in high throughput and ultra high throughput screening applications for detection and analysis of protein activity for research purposes.
Advertisement